Dusquetide TFA SGX942 TFA|西域试剂

Dusquetide TFA SGX942 TFA

产品编号：Bellancom-P2076A| 分子式：C₂₇H₄₈F₃N₉O₇| 分子量：667.72

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P2076A	￥2200.00	杭州北京（现货）
Bellancom-P2076A	￥5600.00	杭州北京（现货）
Bellancom-P2076A	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Dusquetide TFA SGX942 TFA

产品介绍

Dusquetide (SGX942) TFA 是第一类天然防御调节因子 (IDR)。Dusquetide TFA 通过与 p62 结合调节 PAMPs 和 DAMPs 的天然免疫应答。Dusquetide TFA 在减轻炎症和增加细菌感染清除方面都显示出活性。

生物活性

Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

体外研究

体内研究

Dusquetide (SGX942) TFA (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice (MCF-7 tumor xenografts)
Dosage:	25 mg/kg
Administration:	I.v.; days 0, 4, 7, 10, and 14
Result:	Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice (MCF-7 tumor xenografts)
Dosage:	25 mg/kg
Administration:	I.v.; days 0, 4, 7, 10, and 14
Result:	Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.